No Detail Found!

Procalcitonin Level in COVID-19 Patients: A single center study

Author(s)
Batool Mutar Mahdi Department of Microbiology Research Unit, Al-Kindy College of Medicine University of Baghdad,Baghdad,Iraq
Abstract
Objective: The study the association of procalcitonin (PCT) and c-reactive protein (CRP) levels in COVID19 patients and its role as a guide in progress and management of those patients. Methodology: This cross-sectional study analyzed 200 CIOVID-19 patients in a single privet center in Baghdad, Iraq from January 1, 2021 to January 1, 2022. Demographic data like age, sex, and clinical symptoms were recorded. High sensitivity CRP and PCT in the serum were measured via dry fluorescence immunoassay (Lansionbio-China). Results:  Out of 200 patients, 50 had moderate Covid and 150 had severe disease. Mean serum PCT levels was 0.039±0.05 ng/mL in the moderate group (range 0.011 – 0.067) and 0.43±0.21 ng/mL in the severe group (range 0.211±0.513). Mean serum PCT and CRP levels were higher in severe patients than in moderate patients. Conclusions:  PCT and CRP may be an indicator of disease severity in COVID-19
Publication Details
Page(s) 580-582
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 48, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
COVID, CRP, Procalcitonin, Severity.
References
Wang D,Hu B,Hu C,Zhu F,Liu X,Zhang J .2020 .Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323 : 1061-9.
Galib BA .2019 .SARS-CoV-2(COVID-19). J Fac Med Bagdad, 61 : 91-3.
Mahdi BM .2022 .Asthma as a Risk Factor for the Progression of COVID-19. Acta facultatismedicae Naissensis, 39 : 165-172.
Dawood H,Hwayyiz A,Ibrahim I,Abdul Rahman I. .2021 .The clinical features of COVID - 19 in a group of Iraqi patients: A record review. J Fac Med Bagdad, 63 : 8-12.
Mahdi BM .2020 .COVID-19 type III hypersensitivity reaction. Med Hypotheses, 109763 : 109763.
Allawi JS,Abbas HM,Rasheed JI,Sulaiman TI,Gatea AA,Al-Lami F .2020 .The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study. J Fac Med Bagdad, 61 : 94-9.
Mahdi BM .2021 .9(A. Vaccine Hesitancy and Acceptance among Medical Students: An Online Crosssectional Study in Iraq. Maced J Med Sci, : 955-8.
Mahdi BM,Dermo-Sifiliográficas Attitude. Actas .2022 .Contact Dermatitis from Amplified Hand Hygiene Practices In The COVID-19 Pandemic Among Medical Students: Frequency, Knowledge, and. Available online 11 July, : .
Jesenak M,Brndiarova M,Urbancikova I,Rennerova Z,Vojtkova J,Bobcakova A .2020 .Immune parameters and COVID-19 Infection-Associations with clinical severity and disease prognosis. Front Cell Infect Microbiol, 10 : 364.
Holub M,Lawrence DA,Andersen N,Beran A,O A .2013 .Cytokines and chemokines as biomarkers of community-acquired bacterial infection. Mediators Inflamm, : .
Albrich WC,Harbarth S. Pros .2015 .and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med, 41(10) : 1739-51.
Charles PE,Tinel C,Barbar S,Aho S,Prin S,Doise JM .2009 .Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care, 13 : .
Pink I,Raupach D,Fuge J. .2021 .C-reactive protein and procalcitonin for antimicrobial stewardship in COVID19. Infection, 49 : 935-943.
Lippi G,Plebani M. .2020 .Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta, 505 : 190-1.
Hu R,Han C,Pei S,Yin M,Chen X .2020 .Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents, 10605(2) : 1.
.2020 .State Council of The People's Republic of China. The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (6th edition. , 54 : 8094.
Gandhi RT,Lynch JB,Del Rio C .2020 .. Mild or Moderate Covid-19.N Engl J Med, 383(18) : 1757-1766.
Huang C,Wang Y,Li X,Ren L,Zhao J,Hu Y .2020 .Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 : 497-506.
Mazaheri T,Ranasinghe R,Al-Hasani W. .2022 .A cytokine panel and procalcitonin in COVID-19, a comparison between intensive care and non-intensive care patients. PLoS One, 17(5) : e0266652.
Lippi G,Cervellin G .2018 .Procalcitonin for diagnosing and monitoring bacterial infections: for or against?. Clin Chem Lab Med, 56 : 1193-5.
Cowman K,Rossi J,Gendlina I. Elucidating .2022 .the role of procalcitonin as a biomarker in hospitalized COVID-19 patients. Diagn Microbiol Infect Dis, 103(4) : 115721.
van Berkel M,Kox M,Frenzel T,Pickkers P,Schouten J .2020 .Biomarkers for antimicrobial stewardship: a reappraisal in COVID-. times? Crit Care, 24(1) : 600.
López-Ayala P,Alcaraz-Serna A,Valls Carbó A .2022 .Procalcitonin concentration in the emergency department predicts 30-day mortality in COVID-19 better than the lymphocyte count, the neutrophil-tolymphocyte ratio, or the C-reactive protein level. Procalcitonina es superior a recuentolinfocitario, índiceneutrófilo/linfocito y proteína C reactiva para la predicción de mortalidad a 30 días de pacientes con COVID-. Emergencias, 34 : 119-127.
0

Citations

0

Downloads

38

Views